Hyperfine, Inc. HYPR
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2021 · data as of November 13, 2026
Hyperfine, Inc. (HYPR) is a healthcare company listed in the US with a market value of about $67M. In the twelve months to September 30, 2026 it had revenue of $19M and net income of -$30M, a net margin of -156.4%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 115% a year, a 5-year average ROIC of -66%.
About Hyperfine
Hyperfine is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2021. Revenue went from $294000 in 2020 to $14M in 2025, growth of about 115.2% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 16% over three years (dilution for shareholders). It spends 129% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $19M | $14M | $13M | $11M | $7M | $1M | $294000 |
| Net income | -$30M | -$36M | -$41M | -$44M | -$44M | -$65M | -$23M |
| Free cash flow | -$28M | -$29M | -$39M | -$43M | -$73M | -$50M | -$23M |
| EPS (diluted) | $-0.29 | $-0.43 | $-0.56 | $-0.62 | $-1.04 | $-17.57 | $-15.38 |
| Net margin | -156.4% | -262.3% | -315.9% | -401.0% | -649.2% | -4335.0% | -7968.4% |
| ROIC | — | -89.8% | -87.5% | -56.8% | -59.7% | -34.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Hyperfine pay a dividend?
Not currently.
Is Hyperfine a good stock to buy?
We do not give buy or sell advice. Hyperfine scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.